Sort
48,018 grants matching “immunotherapy”
Role of necroptosis in colorectal cancer therapy
$445,723Lin Zhang · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · CA
Role of necroptosis in colorectal cancer therapy
$445,723Lin Zhang · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Post-translational control of cancer cell stress response and metastasis
$445,719Iannis Aifantis · New York University School Of Medicine · R01 · FY2019 · CA
Immunometabolic pathways enabled by PARP inhibition in breast cancer
$445,716Jennifer L. Guerriero · Brigham And Women'S Hospital · R37 · FY2024 · CA
Proj 4: Triggers for the Induction of T Cell Dysfunction on T cells in Glioblastoma
$445,712Vijay K Kuchroo · Brigham And Women'S Hospital · P01 · FY2020 · CA
Proj 4: Triggers for the Induction of T Cell Dysfunction on T cells in Glioblastoma
$445,712Vijay K Kuchroo · Brigham And Women'S Hospital · P01 · FY2021 · CA
Fast Targeted Spectroscopic Imaging for Brain Tumor Imaging at 3T and 7T
$445,706Hoby P Hetherington · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · EB
Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells
$445,687Jianhua Yu · Beckman Research Institute/City Of Hope · R01 · FY2020 · CA
Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells
$445,687Jianhua Yu · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA
NRG Oncology NCORP Research Base
$445,671Deborah W Bruner · Nrg Oncology Foundation, Inc. · UG1 · FY2019 · CA
Chemoenzymatic synthesis of trehalose analogues as tools for investigating mycobacteria
$445,611Benjamin Michael Swarts · Central Michigan University · R15 · FY2024 · AI
Particulate-based in vivo modulation for immunotherapy of Rheumatoid Arthritis
$445,550Jamal S Lewis · University Of California At Davis · R01 · FY2020 · AI
Oncology Research Career Development Program
$445,536City Of Hope/Beckman Research Institute · K12 · FY2004 · CA
Reversal of neurodegeneration through pTau clearance by chimeric scavenger receptor monocytes
$445,500Michael A. Curran · University Of Tx Md Anderson Can Ctr · R21 · FY2020 · AG
Focused ultrasound and synucleinopathy
$445,500Serge E Przedborski · Columbia University Health Sciences · R21 · FY2019 · NS
Heterlogous Prime and Boost Vaccine Strategies
$445,485Jonathan Smith · Duke University · P01 · FY2006 · CA
CTL-based Immunotherapy in an Organotypic Melanoma Culture System
$445,471Dorothee M Herlyn · Wistar Institute · P50 · FY2007 · CA
Post-translational control of cancer cell stress response and metastasis
$445,437Iannis Aifantis · New York University School Of Medicine · R01 · FY2016 · CA
Induction of Tumor Immunity by Secreted HSP-gp96
$445,429Eckhard R Podack · University Of Miami School Of Medicine · P01 · FY2008 · CA
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma
$445,383Frederick F Lang · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma
$445,383Frederick F Lang · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Developmental Funds
$445,321Suresh S Ramalingam · Emory University · P30 · FY2023 · CA
Calreticulin-mediated protein folding in health and disease
$445,312Malini Raghavan · University Of Michigan At Ann Arbor · R01 · FY2024 · AI
Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic Efficacy
$445,226Zhiguo Li · University Of Kentucky · R01 · FY2022 · CA
Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic Efficacy
$445,226Zhiguo Li · University Of Kentucky · R01 · FY2025 · CA